Loading company…
Malvern-based biotechnology company developing gene therapies and vaccines, including a COVID-19 mucosal vaccine.
Ocugen develops gene and cell therapies and vaccines, including a mucosal COVID-19 vaccine and a modifier gene therapy platform for inherited retinal diseases such as retinitis pigmentosa and Stargardt disease. Founded in 2013 by Shankar Musunuri, the company is headquartered in Malvern, US. In 2022 it raised USD 15.0 mn in a private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in